IMS Health
A healthcare information, technology, and services company that became part of the business now known as IQVIA.
Last updated August 31, 2026
AI crawler reads
6requests
1companies- Anthropic6
- Profile
- 2
- Controversies
- 2
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
IMS Health was a United States-based healthcare information, services, and technology company whose activities formed a major part of the business now operating under the IQVIA name. Founded in 1954 as Intercontinental Marketing Statistics, the company built a global information infrastructure for pharmaceutical and healthcare markets. Its datasets covered pharmaceutical sales, prescription activity, medical claims, electronic medical records, healthcare facilities, and other de-identified or aggregated information. These resources were used by pharmaceutical manufacturers, biotechnology companies, healthcare providers, payers, and investors to understand treatment markets, evaluate commercial performance, identify patient and physician populations, and plan product portfolios. The company became particularly well known for physician prescribing and pharmaceutical market data in the United States. Its business model combined data collection with syndicated market reports, forecasting, consulting, analytics, software, and technology-enabled services. Rather than operating primarily as a drug developer or healthcare provider, IMS Health served as an information and decision-support intermediary for the life-sciences industry. Its offerings supported launch planning, sales-force effectiveness, market measurement, health economics and outcomes research, pricing, reimbursement analysis, and commercial strategy. IMS Health expanded through a long series of acquisitions. These transactions broadened its capabilities from traditional market statistics into patient-centric claims data, healthcare facility information, analytics, software-as-a-service products, customer relationship management, social-media analysis, clinical-trial planning, payer services, and pharmaceutical transaction intelligence. The company also developed a broad international footprint, including operations and acquisitions in Europe, Canada, China, India, Russia, and other markets. The company experienced several changes in ownership and corporate structure. Its former parent, Cognizant Corporation, separated IMS Health and Nielsen Media Research in 1998. IMS Health subsequently divested its stake in Cognizant Technology Solutions in 2003, leaving the two companies independent. In 2010, a consortium consisting of TPG Capital, the Canada Pension Plan Investment Board, and Leonard Green & Partners took IMS Health private. The company returned to the public markets in 2014, listing on the New York Stock Exchange under the symbol IMS. In 2016, IMS Health merged with Quintiles, a major contract research and clinical development services company. The combined organization was initially named QuintilesIMS, bringing together IMS Health's healthcare data and commercial capabilities with Quintiles' clinical research and contract development operations. On November 6, 2017, the company adopted the name IQVIA. Accordingly, IMS Health is best understood as the historical corporate entity and principal predecessor represented by the authoritative Wikipedia subject, while IQVIA is the continuing successor brand and public company. The historical IMS Health business ended as a standalone brand after the Quintiles combination and subsequent rebranding.
History
IMS Health originated in 1954 as Intercontinental Marketing Statistics, a name reflected in the initials IMS. Founded by Bill Frohlich and David Dubow, the company developed a business around collecting, organizing, and interpreting information about pharmaceutical markets. Its data became especially significant in the United States, where IMS Health was recognized as the largest supplier of physician prescribing information. Over time, the company expanded beyond prescription statistics into pharmaceutical sales measurement, medical claims, electronic medical records, healthcare facility profiles, and other forms of de-identified or aggregated healthcare information. IMS Health's customers used its information to estimate market size, forecast demand, compare product performance, identify treatment and prescriber patterns, plan product launches, and allocate commercial resources. The company combined proprietary datasets with consulting and analytical services, producing syndicated reports as well as client-specific studies. Its scope gradually broadened to include health economics and outcomes research, payer services, commercial effectiveness, customer relationship management, clinical-trial planning, and software-supported analytics. Corporate restructuring marked several important stages in the company's development. In 1998, the former parent Cognizant Corporation separated IMS Health from Nielsen Media Research. IMS Health retained a connection to Cognizant Technology Solutions for a period, but sold its entire stake in 2003, making the two organizations independent. The company pursued extensive acquisition activity during the 2000s and 2010s. Acquisitions added pharmaceutical consulting, forecasting, patient-level claims, healthcare facility data, international market intelligence, clinical-trial enrollment tools, payer analytics, software-as-a-service products, customer relationship management, social-media monitoring, and pharmaceutical transaction information. In February 2010, IMS Health was acquired by TPG Capital, the Canada Pension Plan Investment Board, and Leonard Green & Partners. It later returned to the public markets on April 4, 2014, trading on the New York Stock Exchange under the symbol IMS. The company continued to enlarge its software, diagnostics-market, data-management, and consulting portfolio through additional acquisitions, including purchases connected with Cegedim's CRM and strategic data activities, Dataline Software, and Boston Biomedical Consultants. A decisive transformation came in 2016, when IMS Health merged with Quintiles. The transaction combined a healthcare information and commercial-services business with a large clinical research organization. The merged company was named QuintilesIMS and had a reported ownership split in which former IMS Health shareholders held the larger portion. On November 6, 2017, QuintilesIMS adopted the name IQVIA. This rebranding marked the end of IMS Health as a standalone corporate identity, while preserving its data, analytics, technology, and commercial-services activities within IQVIA. IMS Health's data practices also generated controversy. Critics and litigants questioned the privacy implications and commercial use of prescribing information, even when the information was anonymized or aggregated. The company was involved in IMS Health v. Ayotte and Sorrell v. IMS Health Inc. The latter reached the United States Supreme Court and concerned restrictions on the use of physician-identifying prescription information for pharmaceutical marketing. The Court ruled in favor of IMS Health on free-speech grounds. These disputes helped make IMS Health an important case study in the tension between data-driven healthcare commerce, physician privacy, public-health information, and commercial speech.
- 2017
Rebranded as IQVIA
[1]QuintilesIMS adopted the IQVIA name on November 6.
- 2016
Merger with Quintiles
[1]The merger created the combined company QuintilesIMS.
- 2014
Return to public trading
[1]IMS Health listed on the New York Stock Exchange under the ticker IMS.
- 2010
IMS Health taken private
[1]A consortium led by TPG Capital acquired the company.
- 2003
IMS Health and Cognizant became independent
[1]IMS Health sold its remaining 56 percent stake in Cognizant Technology Solutions.
- 1998
Cognizant Corporation restructured
[1]Cognizant Corporation separated IMS Health and Nielsen Media Research into distinct businesses.
- 1954
Intercontinental Marketing Statistics founded
[1]The company that later became IMS Health was established by Bill Frohlich and David Dubow.
Products and positioning
Premium, data-intensive healthcare intelligence and life-sciences services provider
Healthcare data
Pharmaceutical market intelligence
IMS Health's core business measured pharmaceutical sales, prescriptions, and market activity across countries and therapeutic areas. These datasets supported market sizing, competitive analysis, forecasting, sales-force planning, product-launch preparation, and evaluation of commercial performance. The information was delivered through syndicated reports, databases, and analytical services.
Real-world evidence · 2005
Patient-centric claims and real-world data
Through its own data assets and acquisitions such as PharMetrics and SDI Health, IMS Health developed patient-level and claims-based capabilities. These resources enabled analysis of treatment pathways, utilization, outcomes, payer behavior, and patient populations, subject to applicable privacy and data-use constraints.
Clinical research technology · 2012
Clinical trial planning and enrollment technology
Acquisitions including DecisionView and TTC expanded IMS Health's ability to help life-sciences organizations plan clinical-trial enrollment, monitor recruitment, benchmark trial costs, and negotiate development-related expenditures.
Healthcare software · 2013
Commercial software and healthcare CRM
IMS Health broadened its software portfolio through acquisitions involving sales-performance management, multichannel customer relationship management, relationship marketing, and social-media analytics. These tools supported interactions among pharmaceutical companies, physicians, payers, and other healthcare stakeholders.
Healthcare consulting · 2007
Health economics and outcomes research
The company provided analytical and consulting capabilities for assessing treatment value, healthcare utilization, outcomes, and reimbursement considerations. These services helped life-sciences clients connect clinical evidence with payer, policy, and market-access decisions.
Controversies
Disputes over prescribing-data privacy and commercial speech
IMS Health's collection and use of prescribing information generated privacy and free-speech controversy. In Sorrell v. IMS Health Inc., the United States Supreme Court considered a Vermont restriction on the sale, disclosure, and use of physician-identifying prescription information for pharmaceutical marketing. The Court ruled in favor of IMS Health, holding that the restriction violated the First Amendment. The company was also involved in IMS Health v. Ayotte.
Brand decisions
2017
Adopt the IQVIA identityStrategyBackground
Following the IMS Health–Quintiles combination, the company needed a unified identity representing data, technology, analytics, and clinical research.
Action taken
QuintilesIMS changed its name to IQVIA on November 6, 2017.
Aftermath
IMS Health ceased to operate as the standalone corporate brand represented by the historical Wikipedia article.
2016
Merge with QuintilesM&ABackground
IMS Health sought to combine healthcare data, analytics, and commercial services with Quintiles' clinical research and contract development capabilities.
Action taken
The companies merged and created QuintilesIMS.
Aftermath
The combined organization was renamed IQVIA in 2017 and continued under the IQV ticker.
Reported combined company value. $17.6 billion (2016)
2014
Return to public marketsStrategyBackground
After several years under private ownership, IMS Health pursued a new public listing.
Action taken
The company listed on the New York Stock Exchange under the symbol IMS.
Aftermath
The listing restored IMS Health's status as a public company until its combination with Quintiles.
2010
Accept a take-private transactionM&ABackground
IMS Health was acquired after operating as a public company and entered private ownership under a consortium of financial sponsors.
Action taken
TPG Capital, the Canada Pension Plan Investment Board, and Leonard Green & Partners took the company private.
Aftermath
IMS Health later returned to public trading in 2014.
Recent events
Reported
Anteris partners with IQVIA and CRF for FDA feasibility study[2]
Anteris Technologies partnered with IQVIA and the Cardiovascular Research Foundation to help conduct an FDA early feasibility study of its DurAVR THV System.
Reported
IQVIA Biotech launches in Japan and Asia Pacific[3]
IQVIA announced the expansion of IQVIA Biotech, its integrated clinical and commercial solutions offering for biotech and emerging biopharma companies, into Japan and Asia Pacific.
- Unconfirmed
Reported
IQVIA acquires Quest Diagnostics’ Q2 Solutions stake[4]
IQVIA acquired Quest Diagnostics’ 40 percent minority share of Q2 Solutions for $760 million, resulting in IQVIA owning 100 percent. Quest Diagnostics was to remain Q2 Solutions clients’ strategic preferred laboratory provider under a multi-year agreement.
Reported
IQVIA revises 2020 guidance[5]
IQVIA said it now expects full-year 2020 revenue of $10.60 billion to $10.925 billion, adjusted EBITDA of $2.20 billion to $2.30 billion, and adjusted earnings per share of $5.75 to $6.10. The guidance includes the estimated impact of general business disruption caused by COVID-19.
Reported
IQVIA launches FluSTAR mobile app[6]
IQVIA announced the launch of FluSTAR, a mobile application providing current flu and cold information to help consumers understand and track illness severity.
Reported
BC Platforms closes $15 million Series C financing[7]
BC Platforms announced that it had closed a USD $15 million financing round led by IQVIA alongside Debiopharm Innovation Fund and Tesi.
Reported
BC Platforms and IQVIA announce genomics analytics collaboration[7]
BC Platforms and IQVIA announced a commercial collaboration to combine their technologies and data capabilities. The companies plan to launch data-driven technologies integrating clinical and genomic data.
Sources8 sources
- 1IMS Healthen.wikipedia.org
- 2Anteris 与 IQVIA 和 CRF 合作开展 FDA 可行性研究proactiveinvestors.com.au
- 3IQVIA Biotech拓展至日本及亚太地区health.economictimes.indiatimes.com
- 4IQVIA收购Quest Diagnostics持有的Q2 Solutions股份finanznachrichten.de
- 5IQVIA调整2020年业绩指引finanznachrichten.de
- 6IQVIA推出FluSTAR移动应用investingnews.com
- 7BC Platforms完成1500万美元C轮融资biotechnewswire.ai
- 8IQVIA Raises Full-year Guidancefinanznachrichten.de
Cite this profile: Cite the canonical profile. /brand-wiki/iqvia · Editorial policy · How profiles are compiled